» Articles » PMID: 34630704

Methylation-dependent Expression of a Variant Ligand and Receptor of the Ghrelin System Induces Thymoma Tumorigenesis

Overview
Journal Oncol Lett
Specialty Oncology
Date 2021 Oct 11
PMID 34630704
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Our previous study reported that the DNA methylation of growth hormone secretagogue receptor () was significantly higher in thymoma or thymic carcinoma (TC) than in normal thymic tissue samples. Thymic epithelial tumors (TETs) with higher DNA methylation were associated with significantly worse prognosis than those with lower levels of DNA methylation. Diversified components of the ghrelin- axis may exert opposing effects in cancer progression, depending on the cancer type in question. However, the precise function of the axis remains unclear. In the present study, the mRNA expression of five key components of the ghrelin system [native ligand ghrelin, variant ligand In-1 ghrelin, native receptor GHSR1a, variant receptor GHSR1b and acylation enzyme ghrelin O-acyltransferase (GOAT)] were examined in 58 TET samples by reverse transcription-quantitative PCR, and protein expression of GHSR1a and GHSR1b was assessed in 20 TETs using immunohistochemistry. The results revealed that In-1 ghrelin, GHSR1b (variant forms) and GOAT were more strongly expressed in thymoma compared with thymic-adjacent tissue. By contrast, no significant differences were observed in the expression of ghrelin and GHSR1a (native forms) between thymoma and thymic tissue. The mRNA expression of In-1 ghrelin and GHSR1b (variant forms) was positively associated with methylation in thymoma tissue samples. However, a relationship was not found between ghrelin, GHSR1a or GOAT expression (native forms) and methylation in thymoma. Immunohistochemical analysis revealed that mRNA expression of GHSR1a and GHSR1b generally correlated with expression of the corresponding protein, and that the expression of GHSR1b was increased in advanced-stage TETs. These results indicate that the DNA methylation of is associated with a shift from native expression (ghrelin and GHSR1a) to variant expression (In-1 ghrelin and GHSR1b), which induces the tumorigenesis of thymoma, but not TC.

Citing Articles

DNA methylation analysis of multiple genes in thymic epithelial tumors.

Nicoli V, Giangreco M, Pardini E, Petrini I, Bacchin D, Aprile V Epigenomics. 2024; 16(21-22):1337-1350.

PMID: 39513235 PMC: 11706250. DOI: 10.1080/17501911.2024.2419362.


A case control study investigating the methylation levels of GHRL and GHSR genes in alcohol use disorder.

Ozkan-Kotiloglu S, Kaya-Akyuzlu D, Guven E, Dogan O, Agtas-Ertan E, Ozgur-Ilhan I Mol Biol Rep. 2024; 51(1):663.

PMID: 38771494 DOI: 10.1007/s11033-024-09585-4.


Epigenetics of Thymic Epithelial Tumors.

Nicoli V, Coppede F Cancers (Basel). 2023; 15(2).

PMID: 36672310 PMC: 9856807. DOI: 10.3390/cancers15020360.


Thymic Epithelial Neoplasms: Focusing on the Epigenetic Alterations.

Psilopatis I, Pergaris A, Vrettou K, Theocharis S, Troungos C Int J Mol Sci. 2022; 23(7).

PMID: 35409405 PMC: 8999627. DOI: 10.3390/ijms23074045.

References
1.
Suzuki E, Sasaki H, Kawano O, Endo K, Haneda H, Yukiue H . Expression and mutation statuses of epidermal growth factor receptor in thymic epithelial tumors. Jpn J Clin Oncol. 2006; 36(6):351-6. DOI: 10.1093/jjco/hyl028. View

2.
Jones P, Baylin S . The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002; 3(6):415-28. DOI: 10.1038/nrg816. View

3.
Luque R, Sampedro-Nunez M, Gahete M, Ramos-Levi A, Ibanez-Costa A, Rivero-Cortes E . In1-ghrelin, a splice variant of ghrelin gene, is associated with the evolution and aggressiveness of human neuroendocrine tumors: Evidence from clinical, cellular and molecular parameters. Oncotarget. 2015; 6(23):19619-33. PMC: 4637309. DOI: 10.18632/oncotarget.4316. View

4.
Cassoni P, Papotti M, Ghe C, Catapano F, Sapino A, Graziani A . Identification, characterization, and biological activity of specific receptors for natural (ghrelin) and synthetic growth hormone secretagogues and analogs in human breast carcinomas and cell lines. J Clin Endocrinol Metab. 2001; 86(4):1738-45. DOI: 10.1210/jcem.86.4.7402. View

5.
Kelly R, Petrini I, Rajan A, Wang Y, Giaccone G . Thymic malignancies: from clinical management to targeted therapies. J Clin Oncol. 2011; 29(36):4820-7. PMC: 3675690. DOI: 10.1200/JCO.2011.36.0487. View